Loading...
•
Dec 31, 2020
Bluebird Bio Q4 2020 Earnings Report
Reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020, and shared recent operational progress.
Key Takeaways
Bluebird Bio reported Q4 2020 financial results, with total revenues increasing slightly to $10.7 million compared to $10.0 million in Q4 2019. The company experienced a net loss of $199.9 million, a slight improvement from the $223.3 million loss in the same period of the previous year. The report highlights the first commercial infusion of ZYNTEGLO in Germany and updates on clinical holds and business separation plans.
bluebird bio announced the first commercial infusion of ZYNTEGLO in Germany.
The FDA placed clinical studies of LentiGlobin for SCD on clinical hold due to safety concerns.
bluebird bio intends to separate its severe genetic disease and oncology businesses into two independent, publicly traded companies by year-end 2021.
The company is on track to complete its BLA submission to the U.S. FDA for beti-cel and eli-cel in mid-2021.
Bluebird Bio
Bluebird Bio
Forward Guidance
bluebird bio anticipates several milestones, including regulatory decisions and clinical data updates. However, the company faces challenges including the clinical hold on LentiGlobin studies and the ongoing investigation into safety events.
Positive Outlook
- FDA PDUFA goal date of March 27, 2021, for ide-cel approval in multiple myeloma.
- Potential EU approval for eli-cel in CALD mid-year.
- Planned US filings for β-thalassemia and CALD later in the year.
- Updated data from ongoing clinical studies in patients with TDT in mid-2021.
- Submission of 1 - 2 investigational new drug (IND) applications by the end of 2021.
Challenges Ahead
- Clinical hold on Phase 1/2 and Phase 3 studies of LentiGlobin gene therapy for sickle cell disease.
- Temporary suspension of marketing of ZYNTEGLO in Europe.
- Ongoing investigation of safety events in HGB-206 study.
- Risk of delays in regulatory submissions due to safety concerns.
- Uncertainty regarding the impact of the COVID-19 pandemic on operations and plans.